Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), calls for prompt and accurate diagnosis and rapid turnaround time for test results to limit transmission. Here, we evaluated two independent molecular assays, the Biomem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chukwunonso Onyilagha, Henna Mistry, Peter Marszal, Mathieu Pinette, Darwyn Kobasa, Nikesh Tailor, Yohannes Berhane, Charles Nfon, Bradley Pickering, Samira Mubareka, David Bulir, Sylvia Chong, Robert Kozak, Aruna Ambagala
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a17bab77e5ff48acb074e774c53b39f7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a17bab77e5ff48acb074e774c53b39f7
record_format	dspace
spelling	oai:doaj.org-article:a17bab77e5ff48acb074e774c53b39f72021-12-02T13:41:34ZEvaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 210.1038/s41598-021-88625-62045-2322https://doaj.org/article/a17bab77e5ff48acb074e774c53b39f72021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88625-6https://doaj.org/toc/2045-2322Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), calls for prompt and accurate diagnosis and rapid turnaround time for test results to limit transmission. Here, we evaluated two independent molecular assays, the Biomeme SARS-CoV-2 test, and the Precision Biomonitoring TripleLock SARS-CoV-2 test on a field-deployable point-of-care real-time PCR instrument, Franklin three9, in combination with Biomeme M1 Sample Prep Cartridge Kit for RNA 2.0 (M1) manual extraction system for rapid, specific, and sensitive detection of SARS-COV-2 in cell culture, human, and animal clinical samples. The Biomeme SARS-CoV-2 assay, which simultaneously detects two viral targets, the orf1ab and S genes, and the Precision Biomonitoring TripleLock SARS-CoV-2 assay that targets the 5′ untranslated region (5′ UTR) and the envelope (E) gene of SARS-CoV-2 were highly sensitive and detected as low as 15 SARS-CoV-2 genome copies per reaction. In addition, the two assays were specific and showed no cross-reactivity with Middle Eastern respiratory syndrome coronavirus (MERS-CoV), infectious bronchitis virus (IBV), porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis (TGE) virus, and other common human respiratory viruses and bacterial pathogens. Also, both assays were highly reproducible across different operators and instruments. When used to test animal samples, both assays equally detected SARS-CoV-2 genetic materials in the swabs from SARS-CoV-2-infected hamsters. The M1 lysis buffer completely inactivated SARS-CoV-2 within 10 min at room temperature enabling safe handling of clinical samples. Collectively, these results show that the Biomeme and Precision Biomonitoring TripleLock SARS-CoV-2 mobile testing platforms could reliably and promptly detect SARS-CoV-2 in both human and animal clinical samples in approximately an hour and can be used in remote areas or health care settings not traditionally serviced by a microbiology laboratory.Chukwunonso OnyilaghaHenna MistryPeter MarszalMathieu PinetteDarwyn KobasaNikesh TailorYohannes BerhaneCharles NfonBradley PickeringSamira MubarekaDavid BulirSylvia ChongRobert KozakAruna AmbagalaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chukwunonso Onyilagha Henna Mistry Peter Marszal Mathieu Pinette Darwyn Kobasa Nikesh Tailor Yohannes Berhane Charles Nfon Bradley Pickering Samira Mubareka David Bulir Sylvia Chong Robert Kozak Aruna Ambagala Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
description	Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), calls for prompt and accurate diagnosis and rapid turnaround time for test results to limit transmission. Here, we evaluated two independent molecular assays, the Biomeme SARS-CoV-2 test, and the Precision Biomonitoring TripleLock SARS-CoV-2 test on a field-deployable point-of-care real-time PCR instrument, Franklin three9, in combination with Biomeme M1 Sample Prep Cartridge Kit for RNA 2.0 (M1) manual extraction system for rapid, specific, and sensitive detection of SARS-COV-2 in cell culture, human, and animal clinical samples. The Biomeme SARS-CoV-2 assay, which simultaneously detects two viral targets, the orf1ab and S genes, and the Precision Biomonitoring TripleLock SARS-CoV-2 assay that targets the 5′ untranslated region (5′ UTR) and the envelope (E) gene of SARS-CoV-2 were highly sensitive and detected as low as 15 SARS-CoV-2 genome copies per reaction. In addition, the two assays were specific and showed no cross-reactivity with Middle Eastern respiratory syndrome coronavirus (MERS-CoV), infectious bronchitis virus (IBV), porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis (TGE) virus, and other common human respiratory viruses and bacterial pathogens. Also, both assays were highly reproducible across different operators and instruments. When used to test animal samples, both assays equally detected SARS-CoV-2 genetic materials in the swabs from SARS-CoV-2-infected hamsters. The M1 lysis buffer completely inactivated SARS-CoV-2 within 10 min at room temperature enabling safe handling of clinical samples. Collectively, these results show that the Biomeme and Precision Biomonitoring TripleLock SARS-CoV-2 mobile testing platforms could reliably and promptly detect SARS-CoV-2 in both human and animal clinical samples in approximately an hour and can be used in remote areas or health care settings not traditionally serviced by a microbiology laboratory.
format	article
author	Chukwunonso Onyilagha Henna Mistry Peter Marszal Mathieu Pinette Darwyn Kobasa Nikesh Tailor Yohannes Berhane Charles Nfon Bradley Pickering Samira Mubareka David Bulir Sylvia Chong Robert Kozak Aruna Ambagala
author_facet	Chukwunonso Onyilagha Henna Mistry Peter Marszal Mathieu Pinette Darwyn Kobasa Nikesh Tailor Yohannes Berhane Charles Nfon Bradley Pickering Samira Mubareka David Bulir Sylvia Chong Robert Kozak Aruna Ambagala
author_sort	Chukwunonso Onyilagha
title	Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
title_short	Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
title_full	Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
title_fullStr	Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
title_full_unstemmed	Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
title_sort	evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a17bab77e5ff48acb074e774c53b39f7
work_keys_str_mv	AT chukwunonsoonyilagha evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT hennamistry evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT petermarszal evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT mathieupinette evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT darwynkobasa evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT nikeshtailor evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT yohannesberhane evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT charlesnfon evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT bradleypickering evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT samiramubareka evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT davidbulir evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT sylviachong evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT robertkozak evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2 AT arunaambagala evaluationofmobilerealtimepolymerasechainreactiontestsforthedetectionofsevereacuterespiratorysyndromecoronavirus2
_version_	1718392572128264192

Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2

Ejemplares similares